News for Alcon Inc. (ALC.SW)

We came across a bullish thesis on Avantor, Inc. on Valueinvestorsclub.com by Teton0321. In this article, we will summarize the bulls’ thesis on AVTR. Avantor, Inc.’s share was trading at $12.34 as of July 21st. AVTR’s trailing and forward P/E were 11.87 and 11.98, respectively according to Yahoo Finance. Avantor (AVTR) appears deeply oversold, with stock sentiment […]

LENSAR and Alcon's deal presents upside and uncertainty, LENSAR for speculators, Alcon for stability. Check out more on LNSR and ALC stocks here.

Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Strategy” second quarter 2025 investor letter. A copy of the letter can be downloaded here. Although the U.S. equity market started with volatility in the second quarter, it rebounded with strength, with the S&P 500 Index rising 10.94% during the quarter. The composite returned 4.88% […]

PR NewswireNEW YORK, July 22, 2025 MarketNewsUpdates News CommentaryNEW YORK, July 22, 2025 /PRNewswire/ -- According to a report from Research And Markets

An analyst at Berenberg, Sam England, has revised the price target for Alcon (ALC), lowering it from CHF 93 to CHF 90. Despite this adjustment, the analyst main

Morgan Stanley has adjusted its price target for Alcon (ALC), reducing it from $90.00 to $84.00. The adjustment represents a decrease of approximately 6.67% in

Morgan Stanley has adjusted its price target for Alcon (ALC), bringing it down to $84 from a previous target of $90 while maintaining an Equal Weight rating on

BTIG analyst Ryan Zimmerman has increased the price target for Alcon (ALC) to $100, up from the previous $99, while maintaining a "Buy" rating for the stock. Th

Summary Alcon Inc (ALC), a global leader in eye care, announced its intention to acquire LumiThera, Inc., a company known for its light-based innovations in oph

Alcon Inc. (NYSE:ALC) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 20, Alcon Inc. (NYSE:ALC) announced the approval of the Clareon PanOptix Pro intraocular lens for patients in Canada. PanOptix Pro uses proprietary ENLIGHTEN NXT Optical technology to deliver the lowest light scatter and highest light utilization reported for […]

Alcon posts steady growth in Vision Care and Surgical, with new drug and therapy launches ahead but execution risks persist. Read why ALC stock is a hold.

Alcon Inc. (NYSE:ALC) has announced that the U.S.

Alcon (ALC) secures FDA approval for Tryptyr, an innovative treatment for Dry Eye Disease. Analysts foresee a 24.63% upside, with an average target pric

Kepler Cheuvreux has raised its rating for Alcon (ALC), changing its position from Hold to Buy. This upgrade reflects increased confidence in Alcon's potential

Alcon (ALC) is playing a crucial role in supporting the revenue projections for Lifecore (LFCR) through its minimum volume commitments. According to an analyst

The recent data highlights that Alcon (ALC) experienced a significant rise in its indicative borrow rate, climbing by 4.15% with an increment of 0.45. This incr

Revenue: $2.5 billion, up 3% year-over-year.Core Operating Margin: 20.8%.Core Diluted Earnings: $0.73 per share.Surgical Franchise Revenue: $1.3 billion, up 2%

In the latest analyst update, Needham has reiterated its

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Wednesday. Shares of Alcon Inc ALC fell sharply in today's pre-market t...